Uri MD - Novocure Chief Officer

Novocure Management Efficiency

The company has return on total asset (ROA) of (0.0877) % which means that it has lost $0.0877 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4667) %, meaning that it created substantial loss on money invested by shareholders. Novocure's management efficiency ratios could be used to measure how well Novocure manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/19/2025, Return On Tangible Assets is likely to drop to -0.14. In addition to that, Return On Capital Employed is likely to drop to -0.37. At this time, Novocure's Non Current Assets Total are relatively stable compared to the past year. As of 03/19/2025, Non Currrent Assets Other is likely to grow to about 15.3 M, while Net Tangible Assets are likely to drop slightly above 267.8 M.

Similar Executives

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. NovoCure operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 1167 people. Novocure (NVCR) is traded on NASDAQ Exchange in USA. It is located in Neuhofstrasse 21, Baar, Switzerland, 6340 and employs 1,488 people. Novocure is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Novocure Leadership Team

Novocure Stock Performance Indicators

Additional Tools for Novocure Stock Analysis